Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 nov. 2018 16h00 HE | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and...
06 nov. 2018 07h00 HE | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and...
01 nov. 2018 07h00 HE | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides a Business Update

THE WOODLANDS, Texas, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended...
25 oct. 2018 07h00 HE | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 1, 2018

THE WOODLANDS, Texas, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2018 financial results on Thursday, November 1, 2018 before...
16 oct. 2018 08h00 HE | Source: Lexicon Pharmaceuticals, Inc.; Ipsen Biopharmaceuticals Canada Inc.

Lexicon Pharmaceuticals and Ipsen Biopharmaceuticals Canada Inc. Announce Health Canada Approval of XERMELO® (Telotristat Ethyl) for the Treatment of Refractory Carcinoid Syndrome Diarrhea in Combination With Somatostatin Analog Therapy

Approval Enables Availability of First-in-Class Oral Tryptophan Hydroxylase Inhibitor that Sustains Improvement of Carcinoid Syndrome Diarrhea in Adults Inadequately Controlled by Somatostatin Analogs...
24 sept. 2018 07h00 HE | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and...
24 sept. 2018 07h00 HE | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 54th Annual Meeting

THE WOODLANDS, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for sotagliflozin will be presented at the upcoming European...
30 août 2018 07h00 HE | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative...
22 août 2018 16h22 HE | Source: Lexicon Pharmaceuticals, Inc.

UPDATE: Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the...
22 août 2018 16h00 HE | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

BOSTON, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following...

Page précédente